Changes in m6A in Steatotic Liver Disease

Area of Science:

• Epitranscriptomics
• Hepatology
• Molecular Biology

Background:

• Fatty liver disease, encompassing NAFLD and NASH (now MASLD), significantly contributes to global morbidity and mortality.
• Excess nutrition and obesity are key drivers, yet underlying mechanisms and treatments remain limited.
• Reversible RNA modifications, particularly N6-methyladenosine (m6A), are emerging as critical regulators of gene expression in fatty liver.

Purpose of the Study:

• To review the role of m6A 'readers, writers, and erasers' (RWE) in regulating gene expression relevant to fatty liver disease.
• To summarize current technological and bioinformatic methods for detecting m6A modifications in genes implicated in fatty liver.
• To highlight challenges and advancements in understanding epitranscriptomic mechanisms driving fatty liver disease progression.

Main Methods:

• Review of existing literature on m6A modification, RWE, and their impact on mRNA processing, translation, and degradation.
• Analysis of current technologies and bioinformatics approaches for m6A detection in specific genes.
• Synthesis of findings related to m6A regulation in human liver pathologies and fatty liver disease.

Main Results:

• m6A modification and its associated RWE significantly influence various post-transcriptional processes.
• Specific m6A patterns are linked to the pathogenesis of fatty liver disease.
• Technological limitations and bioinformatic challenges currently hinder comprehensive m6A analysis in this context.

Conclusions:

• m6A epitranscriptomic regulation is a critical, yet incompletely understood, factor in fatty liver disease.
• Advancements in detection methods are essential for elucidating m6A's role and developing targeted therapies.
• Further research into m6A RWE is crucial for understanding and treating MASLD.